Shukra Pharmaceuticals financials

·Pharma & HealthChart ›

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY24Mar 2024FY23Mar 2023
58.0——
10.010.04.0
2.72.75.1
50.6——
74.674.658.8
—+26.8%—
19.419.45.4
26.0%26.0%9.1%
17.417.43.5
18.518.54.4
24.9%24.9%7.5%
₹23.00₹23.00₹5.47
—+320.7%—
−5.2−5.23.2
−1.8−1.8−4.5
−7.0−7.0−1.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SHUKRAPHAR₹71.92

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOCMcap ₹58 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Current
last close
Market Capitalization——58.0
- Cash, Equiv & ST Investments4.010.010.0
+ Total Debt5.12.72.7
Enterprise Value——50.6
Revenue58.874.674.6
Growth %, YoY—+26.8—
EBITDA5.419.419.4
Margin %9.1226.0226.02
EBIT3.517.417.4
Net Income4.418.518.5
Margin %7.4924.8624.86
EPS, Adj (current shares)5.4723.0023.00
Growth %, YoY—+320.7—
Cash from Operations3.2-5.2-5.2
Capital Expenditures-4.5-1.8-1.8
Free Cash Flow-1.3-7.0-7.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.

Shukra Pharmaceuticals financials and key ratios

Figures from the company's filings with NSE

In FY24 its consolidated net profit was ₹18.5 crore on revenue of ₹74.6 crore. Promoters held 51.15% of the shares on 30 September 2026.

Shareholding pattern
30 September 2026

Shukra Pharmaceuticals at a glance · consolidated

Promoter holding
51.15%30 September 2026
Free cash flow (FY24)
−₹7 Cr
EPS (FY24)
₹23.00

Questions

What is the Shukra Pharmaceuticals EPS?

Shukra Pharmaceuticals' basic earnings per share (EPS) were ₹23.00 in FY24.

What is the Shukra Pharmaceuticals dividend in 2026 and its record date?

In 2026, Shukra Pharmaceuticals has declared one dividend: ₹0.01 with record date 21 September 2026.

What is the Shukra Pharmaceuticals promoter holding?

Promoters held 51.15% of Shukra Pharmaceuticals on 30 September 2026, according to the shareholding pattern filed with NSE.

What is the Shukra Pharmaceuticals shareholding pattern?

On 30 September 2026, Shukra Pharmaceuticals' shares were held by promoters 51.15%, foreign portfolio investors (FII/FPI) 0.44%, domestic institutions (DII) 0.22% (including mutual funds at 0.00%) and retail and other non-institutional investors 48.20%.

What is the Shukra Pharmaceuticals free cash flow?

In FY24, Shukra Pharmaceuticals generated ₹5.2 crore of cash from operations and spent ₹1.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹7 crore. In FY23 it was −₹1.3 crore.

What is the Shukra Pharmaceuticals revenue and profit in FY24?

In FY24 (April 2023–March 2024), Shukra Pharmaceuticals' consolidated net profit was ₹18.5 crore, up 320.7% from ₹4.4 crore in FY23, on revenue from operations of ₹74.6 crore (up 26.8%).

How does Shukra Pharmaceuticals compare with its peers?

On FY24 consolidated figures, against Kwality Pharmaceuticals: Shukra Pharmaceuticals' operating margin of 23.3% is the higher of the two (Kwality Pharmaceuticals 15.3%; peer average 15.3%).

Where do these Shukra Pharmaceuticals figures come from?

From Shukra Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.